The burgeoning popularity of tirzepatide , initially for diabetes , is creating significant attention within the United Kingdom , prompting a notable shift in hormone trends. Availability these treatments remains a complex situation , with bioactive peptides NHS provision currently limited and independent providers offering therapy at a higher cost